The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
Check out some of NeurologyLive®'s featured content in the carousel below.
Efficacy, Safety of Rimegepant When Used Both as Preventively and As-Need: Richard B. Lipton, MD
July 10th 2022The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]
Understanding the Impact of MiCOAS Qualitative Study: Richard B. Lipton, MD
July 8th 2022The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]
Advocating for Patients With Migraine Through Research Initiatives: Serena L. Orr, MD, MSc
July 7th 2022The pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]
Triptan Use Shows No Significant Vascular Comorbidity Increase for Older Patients With Migraine
July 1st 2022In triptan users, prescriptions of cardiac therapies and beta blockers were significantly more common compared with other prescriptions of calcium channel blockers and renin/angiotensin inhibitors, which were significantly less common.
AbbVie Submits Supplemental New Drug Application for Atogepant in Chronic Migraine
June 22nd 2022Originally approved for the preventive treatment of episodic migraine in Sept 2021, atogepant’s potential new indication stems from positive results from the double-blind, placebo-controlled, phase 3 PROGRESS trial.